1. Exposure-safety and exposure-efficacy analyses of polatuzumab vedotin in patients with relapsed or refractory diffuse large B-cell lymphoma. Issue 12 (14th October 2020) Authors: Lu, Tong; Gibiansky, Leonid; Li, Xiaobin; Li, Chunze; Shi, Rong; Agarwal, Priya; Hirata, Jamie; Miles, Dale; Chanu, Pascal; Girish, Sandhya; Jin, Jin Yan; Lu, Dan Journal: Leukemia & lymphoma Issue: Volume 61:Issue 12(2020) Page Start: 2905 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Exposure–response analysis of venetoclax in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia: pooled results from a phase 1b study and the phase 3 MURANO study. Issue 1 (2nd January 2020) Authors: Deng, Rong; Gibiansky, Leonid; Lu, Tong; Li, Xiaobin; Lu, Dan; Li, Chunze; Girish, Sandhya; Wang, Jue; Boyer, Michelle; Shankar, Noopur; Humphrey, Kathryn; Freise, Kevin J.; Salem, Ahmed Hamed; Seymour, John F.; Kater, Arnon P.; Miles, Dale Journal: Leukemia & lymphoma Issue: Volume 61:Issue 1(2020) Page Start: 56 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Integrated Mechanistic Model of Minimal Residual Disease Kinetics With Venetoclax Therapy in Chronic Lymphocytic Leukemia. Issue 2 (6th September 2020) Authors: Gopalakrishnan, Sathej; Wierda, William; Chyla, Brenda; Menon, Rajeev; Miles, Dale; Humerickhouse, Rod; Awni, Walid; Salem, Ahmed Hamed; Mensing, Sven; Freise, Kevin J. Journal: Clinical pharmacology & therapeutics Issue: Volume 109:Issue 2(2021) Page Start: 424 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Integrated Two‐Analyte Population Pharmacokinetic Model of Polatuzumab Vedotin in Patients With Non‐Hodgkin Lymphoma. (23rd December 2019) Authors: Lu, Dan; Lu, Tong; Gibiansky, Leonid; Li, Xiaobin; Li, Chunze; Agarwal, Priya; Shemesh, Colby S.; Shi, Rong; Dere, Randall C.; Hirata, Jamie; Miles, Dale; Chanu, Pascal; Girish, Sandhya; Jin, Jin Yan Journal: CPT: pharmacometrics & systems pharmacology Issue: Volume 9:Number 1(2020) Page Start: 48 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study. Issue 36 (20th December 2021) Authors: Al-Sawaf, Othman; Zhang, Can; Lu, Tong; Liao, Michael Z.; Panchal, Anesh; Robrecht, Sandra; Ching, Travers; Tandon, Maneesh; Fink, Anna-Maria; Tausch, Eugen; Schneider, Christof; Ritgen, Matthias; Böttcher, Sebastian; Kreuzer, Karl-Anton; Chyla, Brenda; Miles, Dale; Wendtner, Clemens-Martin; Eich... Journal: Journal of clinical oncology Issue: Volume 39:Issue 36(2021) Page Start: 4049 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Model‐Informed Therapeutic Dose Optimization Strategies for Antibody–Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration–Approved Antibody–Drug Conjugates?. Issue 5 (8th July 2021) Authors: Liao, Michael Z.; Lu, Dan; Kågedal, Matts; Miles, Dale; Samineni, Divya; Liu, Stephanie N.; Li, Chunze Journal: Clinical pharmacology & therapeutics Issue: Volume 110:Issue 5(2021) Page Start: 1216 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Pharmacokinetic (PK) drug interaction studies of cabozantinib: Effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK. (2nd June 2015) Authors: Nguyen, Linh; Holland, Jaymes; Miles, Dale; Engel, Caroline; Benrimoh, Natacha; O'Reilly, Terry; Lacy, Steven Journal: Journal of clinical pharmacology Issue: Volume 55:Number 9(2015:Sep.) Page Start: 1012 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Physiologically Based Pharmacokinetic Model‐Informed Drug Development for Polatuzumab Vedotin: Label for Drug‐Drug Interactions Without Dedicated Clinical Trials. (17th November 2020) Authors: Samineni, Divya; Ding, Hao; Ma, Fang; Shi, Rong; Lu, Dan; Miles, Dale; Mao, Jialin; Li, Chunze; Jin, Jin; Wright, Matthew; Girish, Sandhya; Chen, Yuan Other Names: Arya Vikram guestEditor.; Venkatakrishnan Karthik guestEditor. Journal: Journal of clinical pharmacology Issue: Volume 60(2020)Supplement 1 Page Start: S120 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Prediction of Human Pharmacokinetics of Antibody–Drug Conjugates From Nonclinical Data. Issue 5 (11th June 2019) Authors: Li, Chunze; Zhang, Cindy; Deng, Rong; Leipold, Douglas; Li, Dongwei; Latifi, Brandon; Gao, Yuying; Zhang, Crystal; Li, Zao; Miles, Dale; Chen, Shang‐Chiung; Samineni, Divya; Wang, Bei; Agarwal, Priya; Lu, Dan; Prabhu, Saileta; Girish, Sandhya; Kamath, Amrita V. Journal: Clinical and translational science Issue: Volume 12:Issue 5(2019) Page Start: 534 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Venetoclax exposure‐efficacy and exposure‐safety relationships in patients with treatment‐naïve acute myeloid leukemia who are ineligible for intensive chemotherapy. Issue 2 (9th February 2022) Authors: Brackman, Deanna; Eckert, Doerthe; Menon, Rajeev; Salem, Ahmed Hamed; Potluri, Jalaja; Smith, B. Douglas; Wei, Andrew H.; Hayslip, John; Miles, Dale; Mensing, Sven; Gopalakrishnan, Sathej; Zha, Jiuhong Journal: Hematological oncology Issue: Volume 40:Issue 2(2022) Page Start: 269 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗